Torrey Pines Investment Biotech Investor Pharmaceutical Drug Development Start-Ups HDAC-inhibitors CD20 CD16 conjugates CNS AVN 211 lymphoma gosogliptin quisinostat virio HIV HBV Altzheimer Schizophrenia drug formulations CRO pre-clinical clinical

TORREY PINES
INVESTMENT

News About Us Portfolio Team Contacts

Viriom Wins Grant Award To Establish Affiliate In Mainland China

Viriom announces NIH/NIAID and Division of AIDS Collaboration with the Long-Acting/Extended Release Antiviral Resource Program

Snap Bio and i2020 Accelerator (Torrey Pines Investment) Reach Lead Compounds Milestone for Pediatric Oncology and Advanced Liver Cancer Programs

Viriom Signed Licensing Agreement for Indonesia with P.T. Lloyd Pharma

Viriom Files for Market Authorization in China

Viriom Announces New CEO Appointment

Viriom Initiates Phase 1 Clinical Trial of Once Monthly Injectable HIV Treatment

Torrey Pines Investment's i2020 Accelerator to Advance Snap Bio's Selective Kinase Inhibitor Platform for Treatment of Endodermal Cancers and Autoimmune Diseases

Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results

Torrey Pines Invests in 19Labs' Innovative Telehealth 2.0 Point of Care Solutions

Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting

Viriom to Present Pre-Clinical Studies with Elsulfavirine/VM1500A Long-Acting Parenteral and Oral Formulations at the International Conference on HIV/AIDS, STDs & STIs 2018

i2020 to Accelerate Stelvio Therapeutics First-in-Class Epigenetic Platform for Glioblastoma

Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting

Torrey Pines Launches i2020 Accelerator for Early Therapeutics

Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial

Torrey Pines Investment announced today the launch and initial funding of its i2020 Accelerator initiative.

ChemDiv, DZNE and Torrey Pines Investment Launch Inflammasome Discovery Program of Translational Collaboration on Neurodegeneration

ChemDiv and Abbott expand collaboration to develop branded generic pharmaceuticals for high growth emerging markets

ChemDiv, Context Therapeutics and Torrey Pines Investment Announce CNS Co-Development Agreement

Tensha Therapeutics To Be Acquired By Roche

ChemDiv Announces Achievement of a Development Milestone in a Drug Discovery Collaboration With Janssen

BioIntegrator Announced Launch of Neskler® -- a Generic of Novartis MS Blockbuster Gilenya® in Emerging Markets

J.P. Morgan 34th Annual Healthcare Conference

Viriom presented the results of the safety and antiviral effect of its novel drug Elpida® at the EACS-2015 conference in Barcelona

Avineuro LLC  advances its highly selective 5-HT6R antagonist program in Alzheimer Disease

TeaRx launches an innovative anticoagulant Tearexaban

Ron Demuth Interviewed for Nature Drug Discovery News Article

Avelas Biosciences Completes 7.4M Funding

T23 Announces Global License of SCRIPPS’ CD22 Siglec Oncoimmunological Platform for B-cell Tumors

Viriom is Expanding its Portfolio of Novel Antiviral Drugs

ChemRar HighTech Center is featured in Pharmaceutical Executive article “Russia’s Bet on Biopharma”

 

 

Current Portfolio
TPI and ChemRar

TORREY PINES
INVESTMENT

12760 High Bluff Dr, Ste 370, San Diego CA 92130
T: (858) 724-0581   F: (858) 345-3761
News About Us Portfolio Team Contacts